Inebilizumab: all 23 studies that test it
Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Inebilizumab for the Treatment of Patients With Type 1 Autoimmune PancreatitisRecruitingNCT07862075Phase 4
- A Phase 3 Study of Inebilizumab in Participants With Primary Membranous NephropathyRecruitingNCT07851220Phase 3
- CD19-B Cell Depletion in PAIS-ME/CFS PatientsNot yet recruitingNCT07724834Phase 2
- A Trial of Inebilizumab in Participants With Autoimmune HepatitisRecruitingNCT07598825Phase 3
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDNot yet recruitingNCT07222553Phase 2
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingNCT07010302Phase 4
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)RecruitingNCT06987539Phase 2
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesRecruitingNCT06570798Phase 2
- A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersNot yet recruitingNCT06212245Phase 4
- Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum DisorderRecruitingNCT05549258Phase 2
- The ExTINGUISH Trial of Inebilizumab in NMDAR EncephalitisRecruitingNCT04372615Phase 2
- A Study of Inebilizumab Efficacy and Safety in IgG4- Related DiseaseActive, not recruitingNCT04540497Phase 3Results posted
- Myasthenia Gravis Inebilizumab TrialActive, not recruitingNCT04524273Phase 3Results posted
- MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple MyelomaTerminatedNCT03218163Phase 2Results posted
- N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersCompletedNCT02200770Phase 2/3Results posted
- A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell MalignanciesCompletedNCT01957579Phase 1Results posted
- Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple SclerosisCompletedNCT01585766Phase 1Results posted
- A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01466153Phase 2Results posted
- A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01453205Phase 2Results posted
- Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)Active, not recruitingNCT06180278Phase 4
- A Study of MT-0551 in Patients With Systemic SclerosisActive, not recruitingNCT05198557Phase 3
- Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased DonorWithdrawnNCT04174677Phase 2
- A Study of the Safety and Tolerability of MEDI-551 in SclerodermaCompletedNCT00946699Phase 1